Zydus Lifesciences enters into patent licensing agreement with Takeda Pharmaceutical

18 Jul 2024 Evaluate

Zydus Lifesciences has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India.  The drug will be marketed under the brand name Vault in the country. Vault, a potassium competitive acid blocker (P-CAB), will be used to treat Gastroesophageal Reflux Disease (GERD) and other acid-related disorders. 

Under the terms of this agreement, Zydus will be marketing the drug in India. Vonoprazan is approved by the Drugs Controller General of India (DCG)I for the treatment of adults with reflux esophagitis and other Acid Peptic Disorders (APD). 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×